Emergent BioSolutions (EBS) Announces Acceptance of TRU-016 and Bispecific Abstracts for Presentation at 2012 American Society of Hematology Annual Meeting  
11/6/2012 8:41:11 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that three abstracts on its humanized anti-CD37 mono-specific protein therapeutic, TRU-016, and bispecific protein therapeutics have been accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) on December 8-11, 2012 in Atlanta, Georgia. The data accepted for presentation include results from a Phase 1b study evaluating TRU-016 in combination with bendamustine in patients with relapsed chronic lymphocytic leukemia (CLL). Results from this study concluded that TRU-016 in combination with bendamustine was well tolerated and showed a positive response.